Rashed Ghandour

Dr. Rashed Ghandour

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Trends in Cancer
Verified
Journal Article
Closed access
RGRashed Ghandour
Rashed Ghandour
NSNirmish Singla
Nirmish Singla
YLYair Lotan
Yair Lotan

1 October 2014 in Urology
Verified
Journal Article
Closed access
SWSolomon L. Woldu
Solomon L. Woldu
AWAaron C. Weinberg
Aaron C. Weinberg
RKRuslan Korets
Ruslan Korets
RGRashed Ghandour
Rashed Ghandour
MDMatthew R. Danzig
Matthew R. Danzig
JMJames M. McKiernan
James M. McKiernan

Verified
Journal Article
Open access
PDF file
JTJennifer Tse
Jennifer Tse
RGRashed Ghandour
Rashed Ghandour
NSNirmish Singla
Nirmish Singla
YLYair Lotan
Yair Lotan
Urothelial carcinoma of the bladder (UCB) and upper tracts (UTUC) is often regarded as one entity and is managed generally with similar principles. While neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is an established standard of care in UCB, strong evidence for a similar approach is lacking in UTUC. The longest survival is seen in patients with complete response (pT0) on pathological examination of the RC specimen, but impact of delayed RC in nonresponders may be detrimental. The rate of pT0 following NAC in UTUC is considerably lower than that in UCB due to differences in access and instrumentation. Molecular markers have been evaluated to try to predict response to chemotherapy to reduce unnecessary treatment and expedite different treatment for nonresponders. A variety of potential biomarkers have been evaluated to predict response to cisplatin based chemotherapy including DNA repair genes (ATM, RB1, FANCC, ERCC2, BRCA1, and ERCC1), regulators of apoptosis (survivin, Bcl-xL, and emmprin), receptor tyrosine kinases (EGFR and erbB2), genes involved in cellular efflux (MDR1 and CTR1), in addition to molecular subtypes (Basal, luminal, and p53-like). The current state of the literature on the prediction of response to NAC based on the presence of these biomarkers is discussed in this review.

1 September 2014 in Urology
Verified
Journal Article
Closed access
MDMatthew R. Danzig
Matthew R. Danzig
AWAaron C. Weinberg
Aaron C. Weinberg
RGRashed Ghandour
Rashed Ghandour
SKSrinath Kotamarti
Srinath Kotamarti
JMJames M. McKiernan
James M. McKiernan
KBKetan K. Badani
Ketan K. Badani

1 January 2015 in Urology
Verified
Journal Article
Closed access
TPTomy Y. Perez
Tomy Y. Perez
MDMatthew R. Danzig
Matthew R. Danzig
RGRashed Ghandour
Rashed Ghandour
KBKetan K. Badani
Ketan K. Badani
MBMitchell C. Benson
Mitchell C. Benson
JMJames M. McKiernan
James M. McKiernan

7 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDivya Bezwada
Divya Bezwada
NLNicholas P. Lesner
Nicholas P. Lesner
BBBrooks Bailey
Brooks Bailey
DVDanny Vu
Danny Vu
ZWZheng Wu
Zheng Wu
RDRalph J. DeBerardinis
Ralph J. DeBerardinis
Summary: Most kidney cancers display evidence of metabolic dysfunction 1–4 but how this relates to cancer progression in humans is unknown. We used a multidisciplinary approach to infuse 13 C-labeled nutrients during surgical tumour resection in over 70 patients with kidney cancer. Labeling from [U- 13 C]glucose varies across cancer subtypes, indicating that the kidney environment alone cannot account for all metabolic reprogramming in these tumours. Compared to the adjacent kidney, clear cell renal cell carcinomas (ccRCC) display suppressed labelling of tricarboxylic acid (TCA) cycle intermediates in vivo and in organotypic slices cultured ex vivo, indicating that suppressed labeling is tissue intrinsic. Infusions of [1,2- 13 C]acetate and [U- 13 C]glutamine in patients, coupled with respiratory flux of mitochondria isolated from kidney and tumour tissue, reveal primary defects in mitochondrial function in human ccRCC. However, ccRCC metastases unexpectedly have enhanced labeling of TCA cycle intermediates compared to primary ccRCCs, indicating a divergent metabolic program during ccRCC metastasis in patients. In mice, stimulating respiration in ccRCC cells is sufficient to promote metastatic colonization. Altogether, these findings indicate that metabolic properties evolve during human kidney cancer progression, and suggest that mitochondrial respiration may be limiting for ccRCC metastasis but not for ccRCC growth at the site of origin.